VECTIVBIO HOLDING AG
VECTIVBIO HOLDING AG logo
VECT

VECTIVBIO HOLDING AG (VECT)

$7.763.05%

Market is closed
– opens on 8 PM, 31 Jan 2023
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$7.53
Day's Range
$8.02
$3.81
52-Week Range
$9.45
1 month return11.42%
3 month return10.19%
1 year return60.66%
5 year return67.97%

Analyst Recommendation

based on 11 analysts ratings

Buy
90%
Buy
9%
Hold
0%
Sell

Based on 11 Wall street analysts offering stock ratings for VECTIVBIO HOLDING AG(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 185.7%

Current

$7.76

Target

$22.17

Recommendation Trend

Based on 11 analyst

Current1M Ago3M Ago
Buy
10
10
9
Hold
1
1
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Highlights

Market Capitalization472.4M
Book Value$3.08
Dividend Share0.0
Dividend Yield0.0%
Earnings Per Share (EPS)-3.23
PEG Ratio0.0
Wall Street Target Price22.17

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)3.62
Enterprise Value371.9M
Enterprise Value/Revenue14.37
Enterprise Value/Ebitda-5.21

Technicals

50 Day MA8.26
200 Day MA6.49

Institutional Holdings

Orbimed Advisors, LLC

10.32%

CHI Advisors LLC

6.57%

Novo A/S

5.32%

Citadel Advisors Llc

5.01%

Bpifrance SA

4.47%

Cormorant Asset Management, LLC

4.04%

Company Information

VectivBio is a global, clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions with high unmet medical need. The company is committed to pursuing product candidates with a clear mechanism of action and the potential to meaningfully transform and improve the lives of patients and their families. VectivBio’s product candidate, apraglutide, is a next-generation GLP-2 analog being developed as a differentiated therapeutic for a range of rare gastrointestinal (GI) diseases. Apraglutide is currently being evaluated in a global phase 3 clinical trial as a once-weekly treatment for short bowel syndrome with intestinal failure (SBS-IF).
OrganizationVECTIVBIO HOLDING AG
Employees0
CEODr. Luca Santarelli M.D.
IndustryHealthcare

Discover more

Frequently Asked Questions

What is VECTIVBIO HOLDING AG share price today?

Can Indians buy VECTIVBIO HOLDING AG shares?

How can I buy VECTIVBIO HOLDING AG shares from India?

Can Fractional shares of VECTIVBIO HOLDING AG be purchased?

What are the documents required to start investing in VECTIVBIO HOLDING AG stocks?

What are today’s High and Low prices of VECTIVBIO HOLDING AG?

What are today’s traded volumes of VECTIVBIO HOLDING AG?

What is today’s market capitalisation of VECTIVBIO HOLDING AG?

What is the 52 Week High and Low Range of VECTIVBIO HOLDING AG?

How much percentage VECTIVBIO HOLDING AG is down from its 52 Week High?

How much percentage VECTIVBIO HOLDING AG is up from its 52 Week low?

What are the historical returns of VECTIVBIO HOLDING AG?

Who is the Chief Executive Officer (CEO) of VECTIVBIO HOLDING AG?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*